De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis

Conditions

• Crohn Disease (CD)
• Ulcerative Colitis (UC)

Interventions

• BIOLOGICAL: Ustekinumab 90 mg SC q8w
• BIOLOGICAL: Ustekinumab 90 mg SC q12w

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborators

• [object Object]